Received Dec 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Intervals between device use too short; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of drug dose administration interval too short in a 18-month-old female patient who received HAV (Havrix 720) for prophylaxis. Previously administered products included Havrix (received Havrix 720 first dose on unknown date). On 24-MAY-2023, the patient received the 2nd dose of Havrix 720 (unknown thigh). On 24-MAY-2023, an unknown time after receiving Havrix 720, the patient experienced drug dose administration interval too short (Verbatim: Intervals between device use too short). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 10-DEC-2025 The patient had second Havrix dose which was administered at 175 days post first dose due to state immunization registry not showing first dose at all. The batch number was not provided, and we are unable to contact the reporter.